Transmitted and Acquired HIV-1 Drug Resistance from a Family: A Case Study

References

• WHO. HIV drug resistance report 2019. Geneva: World Health Organization; 2019 Available from: https://www.who.int/hiv/pub/drugresistance/hivdr-report-2019/en/. Accessed 1222, 2019.
   Google Scholar
• Beyrer C, Pozniak A. HIV drug resistance - an emerging threat to epidemic control. N Engl J Med. 2017;377(17):1605–1607. doi:10.1056/NEJMp171060829069566
   PubMed Web of Science ®Google Scholar
• Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350(10):1023–1035. doi:10.1056/NEJMra02519514999114
   PubMed Web of Science ®Google Scholar
• Paredes R, Clotet B. Clinical management of HIV-1 resistance. Antiviral Res. 2010;85(1):245–265. doi:10.1016/j.antiviral.2009.09.01519808056
   PubMed Web of Science ®Google Scholar
• Yeganeh N, Kerin T, Ank B, et al. Human immunodeficiency virus antiretroviral resistance and transmission in mother-infant pairs enrolled in a large perinatal study. Clin Infect Dis. 2018;66(11):1770–1777. doi:10.1093/cid/cix110429272365
   PubMed Web of Science ®Google Scholar
• WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2016 Available from: https://www.who.int/hiv/pub/arv/arv-2016/en/. Accessed 1222, 2019.
   Google Scholar
• Phillips AN, Cambiano V, Nakagawa F, et al. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. Lancet HIV. 2018;5(3):e146–e154. doi:10.1016/s2352-3018(17)30190-x29174084
   PubMed Web of Science ®Google Scholar
• Young SD, Britcher SF, Tran LO, et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1995;39(12):2602–2605. doi:10.1128/aac.39.12.26028592986
   PubMed Web of Science ®Google Scholar
• Wallis CL, Godfrey C, Fitzgibbon JE, Mellors JW. Key factors influencing the emergence of human immunodeficiency virus drug resistance in low- and middle-income countries. J Infect Dis. 2017;216(suppl_9):S851–s856. doi:10.1093/infdis/jix40929207000
   PubMed Web of Science ®Google Scholar
• Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999;36(1):41–66. doi:10.2165/00003088-199936010-00004
   PubMed Web of Science ®Google Scholar
• Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43(9):595–612. doi:10.2165/00003088-200443090-0000315217303
   PubMed Web of Science ®Google Scholar
• Vrouenraets SM, Wit FW, van Tongeren J, Lange JM. Efavirenz: a review. Expert Opin Pharmacother. 2007;8(6):851–871. doi:10.1517/14656566.8.6.85117425480
   PubMed Web of Science ®Google Scholar
• Delobel P, Saliou A, Nicot F, et al. Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure. PLoS One. 2011;6(6):e21655. doi:10.1371/journal.pone.002165521738752
   PubMed Web of Science ®Google Scholar
• Wittkop L, Gunthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11(5):363–371. doi:10.1016/s1473-3099(11)70032-921354861
   PubMed Web of Science ®Google Scholar
• Vercauteren J, Wensing AM, van de Vijver DA, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis. 2009;200(10):1503–1508. doi:10.1086/64450519835478
   PubMed Web of Science ®Google Scholar
• Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS. 2010;24(8):1203–1212. doi:10.1097/QAD.0b013e328338874220395786
   PubMed Web of Science ®Google Scholar
• Markowitz M, Mohri H, Mehandru S, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet. 2005;365(9464):1031–1038. doi:10.1016/s0140-6736(05)71139-915781098
   PubMed Web of Science ®Google Scholar
• Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008;47(2):266–285. doi:10.1086/58929718549313
   PubMed Web of Science ®Google Scholar
• Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA panel. JAMA. 2018;320(4):379–396. doi:10.1001/jama.2018.843130043070
   PubMed Web of Science ®Google Scholar
• Moscona R, Ram D, Wax M, et al. Comparison between next-generation and Sanger-based sequencing for the detection of transmitted drug-resistance mutations among recently infected HIV-1 patients in Israel, 2000–2014. J Int AIDS Soc. 2017;20(1):21846. doi:10.7448/ias.20.1.2184628799325
   PubMed Web of Science ®Google Scholar
• Tzou PL, Ariyaratne P, Varghese V, et al. Comparison of an in vitro diagnostic next-generation sequencing assay with sanger sequencing for HIV-1 genotypic resistance testing. J Clin Microbiol. 2018;56(6):e00105–00118. doi:10.1128/jcm.00105-1829618499
   PubMed Web of Science ®Google Scholar
• Halvas EK, Aldrovandi GM, Balfe P, et al. Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol. 2006;44(7):2612–2614. doi:10.1128/jcm.00449-0616825395
   PubMed Web of Science ®Google Scholar
• Dykes C, Najjar J, Bosch RJ, et al. Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. J Infect Dis. 2004;189(6):1091–1096. doi:10.1086/38203314999613
   PubMed Web of Science ®Google Scholar
• Lecossier D, Shulman NS, Morand-Joubert L, et al. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr. 2005;38(1):37–42. doi:10.1097/00126334-200501010-0000715608522
   PubMed Web of Science ®Google Scholar
• Halvas EK, Wiegand A, Boltz VF, et al. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. J Infect Dis. 2010;201(5):672–680. doi:10.1086/65054220102272
   PubMed Web of Science ®Google Scholar
• Stekler JD, Milne R, Payant R, et al. Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort. PLoS Med. 2018;15(3):e1002537. doi:10.1371/journal.pmed.100253729584723
   PubMed Web of Science ®Google Scholar
• Workowski K, Bolan G; Prevention. CfDCa. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR–03):1–137.
   PubMed Web of Science ®Google Scholar
• Owens DK, Davidson KW, Krist AH, et al. Screening for hepatitis B virus infection in pregnant women: US preventive services task force reaffirmation recommendation statement. JAMA. 2019;322(4):349–354. doi:10.1001/jama.2019.936531334800
   PubMed Web of Science ®Google Scholar
• Workowski KA, Berman SM. Centers for disease control and prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis. 2007;44(Suppl 3):S73–S76. doi:10.1086/51143017342670
   PubMed Web of Science ®Google Scholar
• Cingolani A, Zona S, Girardi E, et al. Increased incidence of sexually transmitted diseases in the recent years: data from the ICONA cohort. J Int AIDS Soc. 2014;17(4 Suppl 3):19653. doi:10.7448/ias.17.4.1965325394157
   PubMed Web of Science ®Google Scholar
• Cingolani A, Zona S, Girardi E, et al. Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort. HIV Med. 2015;16(7):412–420. doi:10.1111/hiv.1222625959419
   PubMed Web of Science ®Google Scholar
• Tucker JD, Chen XS, Peeling RW. Syphilis and social upheaval in China. N Engl J Med. 2010;362(18):1658–1661. doi:10.1056/NEJMp091114920445179
   PubMed Web of Science ®Google Scholar
• Tang JW, Pillay D. Transmission of HIV-1 drug resistance. J Clin Virol. 2004;30(1):1–10. doi:10.1016/j.jcv.2003.12.00215072747
   PubMed Web of Science ®Google Scholar
• Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS. 1999;13(18):F123–F127. doi:10.1097/00002030-199912240-0000110630517
   PubMed Web of Science ®Google Scholar
• Izopet J, Massip P, Souyris C, et al. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS. 2000;14(15):2247–2255. doi:10.1097/00002030-200010200-0000511089612
   PubMed Web of Science ®Google Scholar
• Charpentier C, Dwyer DE, Mammano F, et al. Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J Virol. 2004;78(8):4234–4247. doi:10.1128/jvi.78.8.4234-4247.200415047838
   PubMed Web of Science ®Google Scholar
• Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 2008;5(7):e158. doi:10.1371/journal.pmed.005015818666824
   PubMed Web of Science ®Google Scholar
• WHO. Update of recommendations on first-and second-line antiretroviral regimens. Geneva: World Health Organization; 2019 Available from: https://www.who.int/hiv/pub/guidelines/en/. Accessed 827, 2020.
   Google Scholar